AR039445A1 - Derivados de pirazina sustituida y su uso - Google Patents

Derivados de pirazina sustituida y su uso

Info

Publication number
AR039445A1
AR039445A1 ARP030101432A ARP030101432A AR039445A1 AR 039445 A1 AR039445 A1 AR 039445A1 AR P030101432 A ARP030101432 A AR P030101432A AR P030101432 A ARP030101432 A AR P030101432A AR 039445 A1 AR039445 A1 AR 039445A1
Authority
AR
Argentina
Prior art keywords
substituted
heteroaryl
heterocycloalkyl
aryl
cycloalkyl
Prior art date
Application number
ARP030101432A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR039445A1 publication Critical patent/AR039445A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S206/00—Special receptacle or package
    • Y10S206/828—Medicinal content

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)

Abstract

Son antagonistas de los receptores CRF1, incluyendo los receptores CRF1 humanos. También está relacionada con el uso de los compuestos para tratar un trastorno o afección cuyo tratamiento se puede lograr o facilitar antagonizando un receptor del CRF, tales como los trastornos o enfermedades del sistema nervioso central, especialmente los trastornos de ansiedad, y la depresión y trastornos relacionados al estrés. Reivindicación 1: Un compuesto de fórmula (1), o un estereoisómero, de dicho compuesto, una sal farmacéuticamente aceptable de dicho compuesto, o un profármaco de dicho compuesto, en donde en la fórmula (1): R1 y R2 se seleccionan independientemente entre halógeno, -NO2,-CN, -Ra, -ORa, -S(O)mRa, -NRaRa, -C(O)NRaRa, -C(S)NRaRa, -S(O)mNRaRa, -NRaS(O)mRa, -NRaC(O)ORa, -NRaC(S)ORa, -OC(O)NRaRa, -OC(S)NRaRa, -NRaC(O)NRaRa, -NRaC(S)NRaRa, -C(O)ORa, -C(S)ORa, OC(O)ORa, o CRaRaAr; X se selecciona entre -NR3R4, -OR3, -CR3R4R5, -C(O)R3, -C(S)R3, -S(O)mR3, -NR3C(O)R4, -NR3C(S)R4, -NR3S(O)mR4, o R3; R3, R4 y R5 se seleccionan independientemente entre Ra, alquilo sustituido, arilo sustituido, heteroarilo sustituido, cicloalquilo sustituido, heterocicloalquilo sustituido, aril-cicloalquilo, aril-cicloalquilo sustituido, heteroaril-cicloalquilo, heteroaril-cicloalquilo sustituido, aril-heterocicloalquilo, aril-heterocicloalquilo sustituido, heteroaril-heterocicloalquilo, o heteroaril-heterocicloalquilo sustituido, cada Ra se selecciona entre H, alquilo, cicloalquilo, haloalquilo, arilo, heteroarilo, o heterocicloalquilo, en donde cada Ra puede estar opcionalmente sustituido con 1 a 5 grupos entre Rt, -ORt, -S(O)mRt, -NRtRt, oxo (=O), tiona (=S); cada Rt se selecciona entre H, halógeno, -NO2, -NH2, -OH, -SH, -CN, -C(O)NH2, -C(S)NH2, -C(O)NHalquilo, -C(S)NHalquilo, -C(O)Nalquilalquilo, -C(S)Nalquilalquilo, -Oalquilo, -NHalquilo, -Nalquilalquilo, -S(O)malquilo, -SO2NH2, -SO2NHalquilo y -SO2Nalquilalquilo, alquilo, cicloalquilo, haloalquilo, fenilo, bencilo, heteroarilo, o heterocicloalquilo en donde el fenilo, bencilo, heteroarilo, y heterocicloalquilo pueden estar opcionalmente sustituidos con alquilo o halógeno; G se selecciona entre un resto del grupo de fórmulas (2) en donde cada grupo G puede tener 1 a 6 sustituyentes independientemente seleccionados entre halógeno, -CN, -NO2, oxo(=O), tiona(=S), -OR5, -SR5, -NR5R5, -C(O)R5, -C(S)R5, -C(O)OR5, -C(S)OR5, -C(O)NR5R5, -C(S)NR5R5, -S(O)mR5, -S(O)2NR5R5, -NR5C(O)R5, -NR5C(S)R5, -NR5C(O)OR5, -NR5C(S)OR5, -NR5C(O)NR5R5, -NR5C(S)NR5R5, -NR5S(O)2R5, -OC(O)R5, -OC(S)R5, -OC(O)OR5, -OC(S)OR5, -OC(O)NR5R5, -OC(S)NR5R5, -CR5R5Ar, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocicloalquilo, o heterocicloalquilo sustituido, y en donde cada grupo G puede tener hasta un enlace doble en su anillo no aromático; Ar se selecciona entre arilo, arilo sustituido, heteroarilo y heteroarilo sustituido; m es 0, 1 ó 2; y n es 0, 1, ó 2.
ARP030101432A 2002-04-26 2003-04-24 Derivados de pirazina sustituida y su uso AR039445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37603102P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
AR039445A1 true AR039445A1 (es) 2005-02-16

Family

ID=29270752

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101432A AR039445A1 (es) 2002-04-26 2003-04-24 Derivados de pirazina sustituida y su uso

Country Status (10)

Country Link
US (1) US6964965B2 (es)
EP (1) EP1499599A1 (es)
JP (1) JP2005533014A (es)
AR (1) AR039445A1 (es)
AU (1) AU2003223475A1 (es)
BR (1) BR0309551A (es)
CA (1) CA2480497A1 (es)
MX (1) MXPA04008384A (es)
TW (1) TW200307672A (es)
WO (1) WO2003091225A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565454A1 (en) * 2002-11-21 2005-08-24 Pharmacia & Upjohn Company LLC Pyrazine compounds as crf modulators
MXPA05012082A (es) 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US7319152B2 (en) 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
KR101118932B1 (ko) 2006-04-14 2012-02-27 아보트 러보러터리즈 바닐로이드 서브타입 1(ｖｒ1) 수용체를 억제하는 인다졸릴우레아의 제조방법
WO2009006245A2 (en) * 2007-07-02 2009-01-08 Smithkline Beecham Corporation Calcilytic compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495343B1 (en) * 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5675033A (en) 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880140A (en) * 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
WO1997036898A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU721952B2 (en) 1996-04-03 2000-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19652246A1 (de) 1996-12-16 1998-06-18 Hoechst Ag 5,7-Difluor-3,4-dihydro-2H-naphthalin-1-on-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19652250A1 (de) 1996-12-16 1998-06-18 Hoechst Ag 1,1,5,7-Tetrafluor-1,2,3,4-tetrahydronaphthalin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19652247A1 (de) 1996-12-16 1998-06-18 Hoechst Ag 5,7-Difluor-1,2,3,4-tetrahydronaphthalin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
EP0951285A1 (en) 1996-12-30 1999-10-27 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
CA2368630A1 (en) 1999-04-02 2000-10-12 Ruth R. Wexler Aryl sulfonyls as factor xa inhibitors
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
AU2001231143A1 (en) 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6995161B2 (en) 2000-02-16 2006-02-07 Neurogen Corporation Substituted arylpyrazines
AU2001284417A1 (en) 2000-09-05 2002-03-22 Taisho Pharmaceutical Co. Ltd. Hair growth stimulants
CA2450262A1 (en) 2001-06-12 2002-12-19 Neurogen Corporation 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators

Also Published As

Publication number Publication date
JP2005533014A (ja) 2005-11-04
BR0309551A (pt) 2005-02-09
CA2480497A1 (en) 2003-11-06
EP1499599A1 (en) 2005-01-26
TW200307672A (en) 2003-12-16
MXPA04008384A (es) 2004-11-26
US20040053941A1 (en) 2004-03-18
US6964965B2 (en) 2005-11-15
WO2003091225A1 (en) 2003-11-06
AU2003223475A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
AR045471A1 (es) Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre
AR046119A1 (es) Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y / o vegf su preparacion y sus usos como medicamento
AR110051A2 (es) Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios
AR069174A1 (es) Derivados de pirazolo[3,4-b]-piridina inhibidores de proteinquinasas, procesos de preparacion, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias o proliferativas.
AR038202A1 (es) Compuestos de indazol utiles como inhibidores de la proteina quinasa
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR079749A2 (es) Derivados de azaindoles heterociclicos inhibidores de quinasas jak-3, aurora a y rock, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades del sistema nervioso central y trastornos inmunologicos y/o alergicos.
AR048501A1 (es) Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
AR040286A1 (es) Proceso para la preparacion de pirimidinas sustituidas
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
AR062510A1 (es) Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos
AR048427A1 (es) Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas.
NI200600257A (es) Nuevos compuestos.
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
UY28150A1 (es) Agentes terapeuticos
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
AR051325A1 (es) Analogos de biarilquinolin-4-ilamina sustituidos
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
AR065863A1 (es) Derivados de imidazolidinona
AR043823A1 (es) Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen
AR092288A1 (es) Ligandos del receptor ep1

Legal Events

Date Code Title Description
FB Suspension of granting procedure